Renal Anemia

Conflicts and Controversies

Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Nephrology, Hematology
Cover of the book Renal Anemia by , Springer Netherlands
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9789401599986
Publisher: Springer Netherlands Publication: June 29, 2013
Imprint: Springer Language: English
Author:
ISBN: 9789401599986
Publisher: Springer Netherlands
Publication: June 29, 2013
Imprint: Springer
Language: English

Is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit? Why have clinicians and nephrologists permitted health insurance companies and the government to decide when anemia therapy should begin in persons with progressive kidney failure? Is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin? Are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment? When does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting? Is darbepoetin alfa, a new novel, long-acting erythropoietin, really superior to recombinant erythropoietin? This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit? Why have clinicians and nephrologists permitted health insurance companies and the government to decide when anemia therapy should begin in persons with progressive kidney failure? Is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin? Are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment? When does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting? Is darbepoetin alfa, a new novel, long-acting erythropoietin, really superior to recombinant erythropoietin? This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management.

More books from Springer Netherlands

Cover of the book Metaphysics, Facticity, Interpretation by
Cover of the book Computational Methods for Corpus Annotation and Analysis by
Cover of the book Three-dimensional structure of wood by
Cover of the book The Application of Neural Networks in the Earth System Sciences by
Cover of the book Modelling Learners and Learning in Science Education by
Cover of the book Therapeutics of Digestive Endoscopic Tunnel Technique by
Cover of the book The Sustainability of Rural Systems by
Cover of the book Phenological Research by
Cover of the book Henry Home, Lord Kames, and the Scottish Enlightenment: A Study in National Character and in the History of Ideas by
Cover of the book Operations Management in Automotive Industries by
Cover of the book International Patent-Legislation and Developing Countries by
Cover of the book Guevara, a Forgotten Renaissance Author by
Cover of the book Environmentally Benign Catalysts by
Cover of the book Plant Geography of Chile by
Cover of the book Conceptual and Methodological Issues on the Adjustment to Aging by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy